IP Library Granted Patent US 11,179,436
Granted Patent B2
US 11,179,436 · App. 16/224,004 · Granted Nov 23, 2021

Methods and compositions comprising a C-terminal Bax peptide

Inventors: Annette Khaled (Orlando, FL); Rebecca Boohaker (Orlando, FL); Michael Lee (Orlando, FL); Jesus Perez Figueroa (Orlando, FL)
Assignee: University of Central Florida Research Foundation, Inc.
A61K38/10A01N43/38A61K9/513A61K38/16A61K38/1761A61K45/06A61P35/00C07K7/08A61K9/5153
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,179,436
App. No.
16/224,004
Granted
Nov 23, 2021
Kind
B2
Abstract

In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.

Claims (11)

1. A method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising a C-terminal B cell lymphoma-2 (Bcl-2)-associated X protein (Bax) peptide (CT20p peptide) and a pharmaceutically acceptable carrier, wherein the CT20p peptide consists of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4; and wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, lung cancer, and liver cancer.

2. The method of claim 1 , further comprising administering to the subject an anti-cancer drug.

3. The method of claim 2 , further comprising administering to the subject a chemotherapeutic drug.

4. The method of claim 2 , further comprising administering to the subject a radiosensitizer.

5. The method of claim 1 , wherein the CT20p peptide is administered directly into the cancer.

6. The method of claim 1 , further comprising repeating the administration of the therapeutically effective amount of the composition comprising the CT20p peptide and the pharmaceutically acceptable carrier.

7. The method of claim 1 , wherein the CT20p peptide is encapsulated in a nanoparticle.

8. The method of claim 7 , wherein the nanoparticle is aminated.

9. The method of claim 7 , wherein the nanoparticle is carboxylated.

10. The method of claim 7 , wherein the nanoparticle is a polymeric nanoparticle.

11. The method of claim 10 , wherein the polymeric nanoparticle is a hyperbranched polymeric (HBPE) nanoparticle.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 21, 2019
From: BOOHAKER, REBECCA; KHALED, ANNETTE; LEE, MICHAEL; FIGUEROA, JESUS PEREZ
To: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 048656/0854 →
CONFIRMATORY LICENSE Recorded Jan 25, 2019
From: UNIVERSITY OF CENTRAL FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 048129/0480 →
Continuity (5)
Continuation 14717884 · May 20, 2015
Continuation 14240801
Provisional Application 61645891 · May 11, 2012
Provisional Application 61527524 · Aug 25, 2011
Related Publication 20190183965A1 · Jun 20, 2019